Our Treatments

Medicine We Develop

Oral for IBD (Crohn’s & Colitis)
Topical for
Psoriasis
Acute Respiratory Distress Syndrome
Our treatments

Creating Better Treatments and Changing Lives

EPM is committed to developing a series of new therapeutic solutions based on cannabinoid acids which provide alternative treatments for patients. This is the driving force behind EPM’s research program. Although cannabinoid acids are potential treatments for a wide range of diseases, currently, EPM focuses on three main therapeutic conditions based on its lead molecule EPM301: Inflammatory Bowel Disease, inflammatory skin disease (psoriasis) and Acute Respiratory Distress Syndrome in COVID-19 patients.

Oral Formulation(Crohn's & Colitis)
Phase I clinical
trial in 2022
Patients in
Europe
Our Treatments

Inflammatory Bowel Disease

Selected formulation

Oral

Expected clinical trail timeline

Phase 1 clinical trail in healthy volunteers anticipated in 2022.

EPM's potential solution

The treatment is based on EPM301 and has been evaluated in both acute (DSS induced mouse colitis) and chronic (IL-10 knock-out mouse) animal models of IBD and has shown similar activity to prednisone (acute model) and anti-TNFa mAb (chronic model) when administered by gavage.

Topical formulation(Psoriasis)
Phase I clinical
trial in 2022
Patients
Worldwide
Our Treatments

Psoriasis

Selected formulation

Topical

Expected clinical trail timeline

Phase 1 clinical trail in healthy volunteers anticipated in 2022.

EPM's potential solution

The treatment is based on EPM301 and has been evaluated in an ex vivo model of inflammatory skin disease. When applied topically, it displayed similar activity to hydrocortisone

IV Formulation
Phase I clinical
trial TBD
People affected
annually
Our Treatments

Acute Respiratory Distress Syndrome

Selected formulation

IV

Expected clinical trail timeline

IND approval to treat COVID-19 patients with poor prognosis under compassionate usage grounds is yet to be defined.

EPM's potential solution

The treatment is based on EPM301 and has demonstrated anti-inflammatory activity in a number of models of inflammatory disease (acute and chronic colitis, inflammatory skin diseases) when administered both orally and topically. EPM301 was also well tolerated in a 7-day IV toxicity study in rats.